Timothy B. Petrick Sells 2,000 Shares of Entellus Medical, Inc. (ENTL) Stock

Entellus Medical, Inc. (NASDAQ:ENTL) VP Timothy B. Petrick sold 2,000 shares of Entellus Medical stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $20.01, for a total transaction of $40,020.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Timothy B. Petrick also recently made the following trade(s):

  • On Friday, September 22nd, Timothy B. Petrick sold 2,000 shares of Entellus Medical stock. The stock was sold at an average price of $18.00, for a total transaction of $36,000.00.

Shares of Entellus Medical, Inc. (NASDAQ:ENTL) opened at 18.74 on Tuesday. The stock’s market capitalization is $475.45 million. The firm has a 50 day moving average of $18.29 and a 200-day moving average of $18.29. Entellus Medical, Inc. has a 12 month low of $11.47 and a 12 month high of $20.69.

Entellus Medical (NASDAQ:ENTL) last posted its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $21.87 million. During the same period in the previous year, the firm posted ($0.27) earnings per share. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. Analysts forecast that Entellus Medical, Inc. will post ($1.61) earnings per share for the current year.

WARNING: “Timothy B. Petrick Sells 2,000 Shares of Entellus Medical, Inc. (ENTL) Stock” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://baseballnewssource.com/markets/timothy-b-petrick-sells-2000-shares-of-entellus-medical-inc-entl-stock/1698155.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Frontier Capital Management Co. LLC lifted its position in shares of Entellus Medical by 85.0% during the second quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock worth $14,347,000 after purchasing an additional 397,953 shares in the last quarter. First Light Asset Management LLC lifted its position in shares of Entellus Medical by 25.7% during the second quarter. First Light Asset Management LLC now owns 512,416 shares of the medical technology company’s stock worth $8,486,000 after purchasing an additional 104,919 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Entellus Medical by 14.2% during the second quarter. Vanguard Group Inc. now owns 485,294 shares of the medical technology company’s stock worth $8,036,000 after purchasing an additional 60,471 shares in the last quarter. Archon Capital Management LLC lifted its position in shares of Entellus Medical by 34.3% during the second quarter. Archon Capital Management LLC now owns 478,820 shares of the medical technology company’s stock worth $7,929,000 after purchasing an additional 122,171 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. lifted its position in shares of Entellus Medical by 79.6% during the first quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock worth $6,215,000 after purchasing an additional 199,615 shares in the last quarter. 70.27% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently issued reports on ENTL. BidaskClub downgraded shares of Entellus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 target price for the company in a research report on Monday, October 9th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $21.00 target price on shares of Entellus Medical in a research report on Tuesday, August 22nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. Entellus Medical presently has an average rating of “Hold” and an average price target of $22.00.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1


Leave a Reply

 
© 2006-2017 BBNS.